Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease

Meysam Yazdankhah, Peng Shang, Sayan Ghosh, Imran A. Bhutto, Nadezda Stepicheva, Rhonda Grebe, Stacey Hose, Joseph Weiss, Tianqi Luo, Subrata Mishra, S. Amer Riazuddin, Arkasubhra Ghosh, James T. Handa, Gerard A. Lutty, J. Samuel Zigler, Debasish Sinha

Research output: Contribution to journalArticle

Abstract

Persistent fetal vasculature (PFV) is a human disease that results from failure of the fetal vasculature to regress normally. The regulatory mechanisms responsible for fetal vascular regression remain obscure, as does the underlying cause of regression failure. However, there are a few animal models that mimic the clinical manifestations of human PFV, which can be used to study different aspects of the disease. One such model is the Nuc1 rat model that arose from a spontaneous mutation in the Cryba1 (crystallin, beta 1) gene and exhibits complete failure of the hyaloid vasculature to regress. Our studies with the Nuc1 rat indicate that macroautophagy/autophagy, a process in eukaryotic cells for degrading dysfunctional components to ensure cellular homeostasis, is severely impaired in Nuc1 ocular astrocytes. Further, we show that CRYBA1 interacts with EGFR (epidermal growth factor receptor) and that loss of this interaction in Nuc1 astrocytes increases EGFR levels. Moreover, our data also show a reduction in EGFR degradation in Nuc1 astrocytes compared to control cells that leads to over-activation of the mechanistic target of rapamycin kinase complex 1 (MTORC1) pathway. The impaired EGFR-MTORC1-autophagy signaling in Nuc1 astrocytes triggers abnormal proliferation and migration. The abnormally migrating astrocytes ensheath the hyaloid artery, contributing to the pathogenesis of PFV in Nuc1, by adversely affecting the vascular remodeling processes essential to regression of the fetal vasculature. Herein, we demonstrate in vivo that gefitinib (EGFR inhibitor) can rescue the PFV phenotype in Nuc1 and may serve as a novel therapy for PFV disease by modulating the EGFR-MTORC1-autophagy pathway. Abbreviations: ACTB: actin, beta; CCND3: cyclin 3; CDK6: cyclin-dependent kinase 6; CHQ: chloroquine; COL4A1: collagen, type IV, alpha 1; CRYBA1: crystallin, beta A1; DAPI: 4ʹ6-diamino-2-phenylindole; EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary growth factor; KDR: kinase insert domain protein receptor; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MKI67: antigen identified by monoclonal antibody Ki 67; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP: poly (ADP-ribose) polymerase family; PCNA: proliferating cell nuclear antigen; PFV: persistent fetal vasculature; PHPV: persistent hyperplastic primary vitreous; RPE: retinal pigmented epithelium; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase, polypeptide 1; SQSTM1/p62: sequestome 1; TUBB: tubulin, beta; VCL: vinculin; VEGFA: vascular endothelial growth factor A; WT: wild type.

Original languageEnglish (US)
JournalAutophagy
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Fetal Diseases
Autophagy
Epidermal Growth Factor Receptor
Phosphotransferases
Astrocytes
beta-Crystallins
Proliferating Cell Nuclear Antigen
Therapeutics
Cyclin-Dependent Kinase 6
Persistent Hyperplastic Primary Vitreous
Ribosomal Protein S6
Neuregulin-1
Ribosomal Protein S6 Kinases
Vinculin
Vascular Endothelial Growth Factor Receptor-2
Glyceraldehyde-3-Phosphate Dehydrogenases
Cyclins
Microtubule-Associated Proteins
Collagen Type IV
Poly(ADP-ribose) Polymerases

Keywords

  • Astrocytes
  • autophagy
  • CRYBA1 (βA3/A1-crystallin)
  • EGFR (epidermal growth factor receptor)
  • gefitinib
  • hyaloid vessels
  • lysosomes
  • MTORC1 (mechanistic target of rapamycin complex 1)
  • Nuc1 rat
  • persistent fetal vasculature (PFV) disease

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease. / Yazdankhah, Meysam; Shang, Peng; Ghosh, Sayan; Bhutto, Imran A.; Stepicheva, Nadezda; Grebe, Rhonda; Hose, Stacey; Weiss, Joseph; Luo, Tianqi; Mishra, Subrata; Riazuddin, S. Amer; Ghosh, Arkasubhra; Handa, James T.; Lutty, Gerard A.; Zigler, J. Samuel; Sinha, Debasish.

In: Autophagy, 01.01.2019.

Research output: Contribution to journalArticle

Yazdankhah, M, Shang, P, Ghosh, S, Bhutto, IA, Stepicheva, N, Grebe, R, Hose, S, Weiss, J, Luo, T, Mishra, S, Riazuddin, SA, Ghosh, A, Handa, JT, Lutty, GA, Zigler, JS & Sinha, D 2019, 'Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease', Autophagy. https://doi.org/10.1080/15548627.2019.1660545
Yazdankhah, Meysam ; Shang, Peng ; Ghosh, Sayan ; Bhutto, Imran A. ; Stepicheva, Nadezda ; Grebe, Rhonda ; Hose, Stacey ; Weiss, Joseph ; Luo, Tianqi ; Mishra, Subrata ; Riazuddin, S. Amer ; Ghosh, Arkasubhra ; Handa, James T. ; Lutty, Gerard A. ; Zigler, J. Samuel ; Sinha, Debasish. / Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease. In: Autophagy. 2019.
@article{39a66de886504e3981c2313f57ade86d,
title = "Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease",
abstract = "Persistent fetal vasculature (PFV) is a human disease that results from failure of the fetal vasculature to regress normally. The regulatory mechanisms responsible for fetal vascular regression remain obscure, as does the underlying cause of regression failure. However, there are a few animal models that mimic the clinical manifestations of human PFV, which can be used to study different aspects of the disease. One such model is the Nuc1 rat model that arose from a spontaneous mutation in the Cryba1 (crystallin, beta 1) gene and exhibits complete failure of the hyaloid vasculature to regress. Our studies with the Nuc1 rat indicate that macroautophagy/autophagy, a process in eukaryotic cells for degrading dysfunctional components to ensure cellular homeostasis, is severely impaired in Nuc1 ocular astrocytes. Further, we show that CRYBA1 interacts with EGFR (epidermal growth factor receptor) and that loss of this interaction in Nuc1 astrocytes increases EGFR levels. Moreover, our data also show a reduction in EGFR degradation in Nuc1 astrocytes compared to control cells that leads to over-activation of the mechanistic target of rapamycin kinase complex 1 (MTORC1) pathway. The impaired EGFR-MTORC1-autophagy signaling in Nuc1 astrocytes triggers abnormal proliferation and migration. The abnormally migrating astrocytes ensheath the hyaloid artery, contributing to the pathogenesis of PFV in Nuc1, by adversely affecting the vascular remodeling processes essential to regression of the fetal vasculature. Herein, we demonstrate in vivo that gefitinib (EGFR inhibitor) can rescue the PFV phenotype in Nuc1 and may serve as a novel therapy for PFV disease by modulating the EGFR-MTORC1-autophagy pathway. Abbreviations: ACTB: actin, beta; CCND3: cyclin 3; CDK6: cyclin-dependent kinase 6; CHQ: chloroquine; COL4A1: collagen, type IV, alpha 1; CRYBA1: crystallin, beta A1; DAPI: 4ʹ6-diamino-2-phenylindole; EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary growth factor; KDR: kinase insert domain protein receptor; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MKI67: antigen identified by monoclonal antibody Ki 67; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP: poly (ADP-ribose) polymerase family; PCNA: proliferating cell nuclear antigen; PFV: persistent fetal vasculature; PHPV: persistent hyperplastic primary vitreous; RPE: retinal pigmented epithelium; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase, polypeptide 1; SQSTM1/p62: sequestome 1; TUBB: tubulin, beta; VCL: vinculin; VEGFA: vascular endothelial growth factor A; WT: wild type.",
keywords = "Astrocytes, autophagy, CRYBA1 (βA3/A1-crystallin), EGFR (epidermal growth factor receptor), gefitinib, hyaloid vessels, lysosomes, MTORC1 (mechanistic target of rapamycin complex 1), Nuc1 rat, persistent fetal vasculature (PFV) disease",
author = "Meysam Yazdankhah and Peng Shang and Sayan Ghosh and Bhutto, {Imran A.} and Nadezda Stepicheva and Rhonda Grebe and Stacey Hose and Joseph Weiss and Tianqi Luo and Subrata Mishra and Riazuddin, {S. Amer} and Arkasubhra Ghosh and Handa, {James T.} and Lutty, {Gerard A.} and Zigler, {J. Samuel} and Debasish Sinha",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/15548627.2019.1660545",
language = "English (US)",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease

AU - Yazdankhah, Meysam

AU - Shang, Peng

AU - Ghosh, Sayan

AU - Bhutto, Imran A.

AU - Stepicheva, Nadezda

AU - Grebe, Rhonda

AU - Hose, Stacey

AU - Weiss, Joseph

AU - Luo, Tianqi

AU - Mishra, Subrata

AU - Riazuddin, S. Amer

AU - Ghosh, Arkasubhra

AU - Handa, James T.

AU - Lutty, Gerard A.

AU - Zigler, J. Samuel

AU - Sinha, Debasish

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Persistent fetal vasculature (PFV) is a human disease that results from failure of the fetal vasculature to regress normally. The regulatory mechanisms responsible for fetal vascular regression remain obscure, as does the underlying cause of regression failure. However, there are a few animal models that mimic the clinical manifestations of human PFV, which can be used to study different aspects of the disease. One such model is the Nuc1 rat model that arose from a spontaneous mutation in the Cryba1 (crystallin, beta 1) gene and exhibits complete failure of the hyaloid vasculature to regress. Our studies with the Nuc1 rat indicate that macroautophagy/autophagy, a process in eukaryotic cells for degrading dysfunctional components to ensure cellular homeostasis, is severely impaired in Nuc1 ocular astrocytes. Further, we show that CRYBA1 interacts with EGFR (epidermal growth factor receptor) and that loss of this interaction in Nuc1 astrocytes increases EGFR levels. Moreover, our data also show a reduction in EGFR degradation in Nuc1 astrocytes compared to control cells that leads to over-activation of the mechanistic target of rapamycin kinase complex 1 (MTORC1) pathway. The impaired EGFR-MTORC1-autophagy signaling in Nuc1 astrocytes triggers abnormal proliferation and migration. The abnormally migrating astrocytes ensheath the hyaloid artery, contributing to the pathogenesis of PFV in Nuc1, by adversely affecting the vascular remodeling processes essential to regression of the fetal vasculature. Herein, we demonstrate in vivo that gefitinib (EGFR inhibitor) can rescue the PFV phenotype in Nuc1 and may serve as a novel therapy for PFV disease by modulating the EGFR-MTORC1-autophagy pathway. Abbreviations: ACTB: actin, beta; CCND3: cyclin 3; CDK6: cyclin-dependent kinase 6; CHQ: chloroquine; COL4A1: collagen, type IV, alpha 1; CRYBA1: crystallin, beta A1; DAPI: 4ʹ6-diamino-2-phenylindole; EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary growth factor; KDR: kinase insert domain protein receptor; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MKI67: antigen identified by monoclonal antibody Ki 67; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP: poly (ADP-ribose) polymerase family; PCNA: proliferating cell nuclear antigen; PFV: persistent fetal vasculature; PHPV: persistent hyperplastic primary vitreous; RPE: retinal pigmented epithelium; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase, polypeptide 1; SQSTM1/p62: sequestome 1; TUBB: tubulin, beta; VCL: vinculin; VEGFA: vascular endothelial growth factor A; WT: wild type.

AB - Persistent fetal vasculature (PFV) is a human disease that results from failure of the fetal vasculature to regress normally. The regulatory mechanisms responsible for fetal vascular regression remain obscure, as does the underlying cause of regression failure. However, there are a few animal models that mimic the clinical manifestations of human PFV, which can be used to study different aspects of the disease. One such model is the Nuc1 rat model that arose from a spontaneous mutation in the Cryba1 (crystallin, beta 1) gene and exhibits complete failure of the hyaloid vasculature to regress. Our studies with the Nuc1 rat indicate that macroautophagy/autophagy, a process in eukaryotic cells for degrading dysfunctional components to ensure cellular homeostasis, is severely impaired in Nuc1 ocular astrocytes. Further, we show that CRYBA1 interacts with EGFR (epidermal growth factor receptor) and that loss of this interaction in Nuc1 astrocytes increases EGFR levels. Moreover, our data also show a reduction in EGFR degradation in Nuc1 astrocytes compared to control cells that leads to over-activation of the mechanistic target of rapamycin kinase complex 1 (MTORC1) pathway. The impaired EGFR-MTORC1-autophagy signaling in Nuc1 astrocytes triggers abnormal proliferation and migration. The abnormally migrating astrocytes ensheath the hyaloid artery, contributing to the pathogenesis of PFV in Nuc1, by adversely affecting the vascular remodeling processes essential to regression of the fetal vasculature. Herein, we demonstrate in vivo that gefitinib (EGFR inhibitor) can rescue the PFV phenotype in Nuc1 and may serve as a novel therapy for PFV disease by modulating the EGFR-MTORC1-autophagy pathway. Abbreviations: ACTB: actin, beta; CCND3: cyclin 3; CDK6: cyclin-dependent kinase 6; CHQ: chloroquine; COL4A1: collagen, type IV, alpha 1; CRYBA1: crystallin, beta A1; DAPI: 4ʹ6-diamino-2-phenylindole; EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFAP: glial fibrillary growth factor; KDR: kinase insert domain protein receptor; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MKI67: antigen identified by monoclonal antibody Ki 67; MTORC1: mechanistic target of rapamycin kinase complex 1; PARP: poly (ADP-ribose) polymerase family; PCNA: proliferating cell nuclear antigen; PFV: persistent fetal vasculature; PHPV: persistent hyperplastic primary vitreous; RPE: retinal pigmented epithelium; RPS6: ribosomal protein S6; RPS6KB1: ribosomal protein S6 kinase, polypeptide 1; SQSTM1/p62: sequestome 1; TUBB: tubulin, beta; VCL: vinculin; VEGFA: vascular endothelial growth factor A; WT: wild type.

KW - Astrocytes

KW - autophagy

KW - CRYBA1 (βA3/A1-crystallin)

KW - EGFR (epidermal growth factor receptor)

KW - gefitinib

KW - hyaloid vessels

KW - lysosomes

KW - MTORC1 (mechanistic target of rapamycin complex 1)

KW - Nuc1 rat

KW - persistent fetal vasculature (PFV) disease

UR - http://www.scopus.com/inward/record.url?scp=85071992110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071992110&partnerID=8YFLogxK

U2 - 10.1080/15548627.2019.1660545

DO - 10.1080/15548627.2019.1660545

M3 - Article

C2 - 31462148

AN - SCOPUS:85071992110

JO - Autophagy

JF - Autophagy

SN - 1554-8627

ER -